Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Vascepa Script Numbers Continue To Build Nicely

|Includes: Amarin Corporation PLC (AMRN), GSK

Vascepa refills up over 12%, double digit base growth too. On track to meet or exceed FY analyst revenue estimates.

Lovaza and Niacin share directly going to Vascepa.

GSK has to be talking to AMRN at this point.